More than two billion people worldwide live with overweight or obesity, conditions closely linked to an array of health ...

Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Viking Therapeutics ( VKTX 4.30%) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's ...

For Robert F. Kennedy Jr., the activist whom President-elect Donald Trump will nominate to serve as the secretary of health and human services, the solution to obesity in America – now at 40% of ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

Viking Therapeutics (VKTX) is identified by Oppenheimer among five potential biotech M&A candidates ahead of J.P. Morgan Healthcare Conference. Read more here.

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy claims.